Compare AVAV & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AVAV | IBRX |
|---|---|---|
| Founded | 1971 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Aerospace | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.8B | 8.2B |
| IPO Year | 2006 | 2015 |
| Metric | AVAV | IBRX |
|---|---|---|
| Price | $153.28 | $8.53 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 17 | 7 |
| Target Price | ★ $316.88 | $12.57 |
| AVG Volume (30 Days) | 1.1M | ★ 8.3M |
| Earning Date | 03-10-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 38.71 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $113,288,000.00 |
| Revenue This Year | $135.55 | $88.59 |
| Revenue Next Year | $14.90 | $131.15 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 668.31 |
| 52 Week Low | $135.20 | $1.95 |
| 52 Week High | $417.86 | $12.43 |
| Indicator | AVAV | IBRX |
|---|---|---|
| Relative Strength Index (RSI) | 41.77 | 62.12 |
| Support Level | $138.24 | $6.68 |
| Resistance Level | $162.30 | $9.57 |
| Average True Range (ATR) | 9.29 | 0.33 |
| MACD | -4.19 | 0.10 |
| Stochastic Oscillator | 11.90 | 80.97 |
AeroVironment Inc is a defense technology provider delivering integrated capabilities across air, land, sea, space, and cyber. It develops and deploys autonomous systems, precision strike systems, counter-UAS technologies, space-based platforms, directed energy systems, and cyber and electronic warfare capabilities. The company operates business in two reportable segments: Autonomous Systems (AxS) and Space, Cyber and Directed Energy (SCDE). It derives majority of revenue from Autonomous Systems segment focuses on the design, development, production, delivery, and support of intelligent, multi-domain robotic systems, including UAS, uncrewed underwater vehicles and ground robot systems. Geographically it derives the majority of revenue from domestic operations.
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.